Shares of Pain Therapeutics (NASDAQ:PTIE) reached a new 52-week high on Friday . The company traded as high as $2.72 and last traded at $2.64, with a volume of 254,050 shares traded. The stock had previously closed at $2.55.

Separately, Zacks Investment Research raised shares of Pain Therapeutics from a “sell” rating to a “hold” rating in a research report on Tuesday, May 31st.

The firm’s market cap is $121.81 million. The firm has a 50 day moving average price of $2.19 and a 200-day moving average price of $2.09.

Pain Therapeutics (NASDAQ:PTIE) last posted its quarterly earnings data on Tuesday, July 19th. The biopharmaceutical company reported ($0.07) EPS for the quarter, topping the consensus estimate of ($0.14) by $0.07. On average, analysts anticipate that Pain Therapeutics will post ($0.54) earnings per share for the current fiscal year.

Pain Therapeutics, Inc is a biopharmaceutical company. The Company is focused on drug development efforts on disorders of the nervous system, such as chronic pain. The Company’s lead drug candidate, REMOXY, is an abuse-deterrent, oral formulation of oxycodone (CII). The Company’s other products is FENROCK.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.